| Overview |
| bs-2235R-Cy3 |
| bFGF Polyclonal Antibody, Cy3 Conjugated |
| FCM, IF(IHC-P), IF(IHC-F), IF(ICC) |
| Human, Mouse, Rat, Dog |
| Cow, Sheep, Pig, Guinea Pig |
| Specifications |
| Cy3 |
| Rabbit |
| Full length of human bFGF Recombinded. |
| 143-288/288 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| 2247 |
| P09038 |
| Nucleus, Secreted |
| Basic fibroblast growth factor; FGF basic; FGF-basic; BFGF; FGF-2; FGF B; FGF2; FGF2 basic; FGFB; Fibroblast growth factor 2 (basic); HBGF 2; HBGF-2; HBGF2; HBGH 2; HBGH2; Heparin binding growth factor 2 precursor; Prostatropin; FGF2_HUMAN. |
| The protein encoded by this gene is a member of the fibroblast growth factor (FGF) family. FGF family members bind heparin and possess broad mitogenic and angiogenic activities. This protein has been implicated in diverse biological processes, such as limb and nervous system development, wound healing, and tumor growth. The mRNA for this gene contains multiple polyadenylation sites, and is alternatively translated from non-AUG (CUG) and AUG initiation codons, resulting in five different isoforms with distinct properties. The CUG-initiated isoforms are localized in the nucleus and are responsible for the intracrine effect, whereas, the AUG-initiated form is mostly cytosolic and is responsible for the paracrine and autocrine effects of this FGF. [provided by RefSeq, Jul 2008]. |
| Application Dilution |
| FCM |
1:20-100 |
| IF(IHC-P) |
1:50-200 |
| IF(IHC-F) |
1:50-200 |
| IF(ICC) |
1:50-200 |
Powered by Bioz